Naltrexone (LDN)

Low-dose naltrexone (LDN) is an off-label application of naltrexone, an opioid receptor antagonist, used at a fraction of its standard dose. At low doses, naltrexone is thought to produce a transient receptor blockade that may trigger a rebound upregulation of endorphin activity and modulate glial cell inflammatory signaling. Because of its proposed effects on central reward pathways and cravings, LDN is sometimes explored by physicians as an adjunct within individualized weight management and wellness protocols. EdgeRx makes LDN available through a clinician-supervised protocol, prescribed by licensed physicians when clinically appropriate based on an individualized health assessment.